ROSARIO CALVO DUO-rekin lankidetzan egindako argitalpenak (8)

2005

  1. Pharmacokinetic-pharmacodynamic modeling of the hydroxy lerisetron metabolite L6-OH in rats: An integrated parent-metabolite model

    Pharmaceutical Research, Vol. 22, Núm. 11, pp. 1769-1782

2003

  1. Age-related changes in pharmacokinetics and pharmacodynamics of lerisetron in the rat: A population pharmacokinetic model

    Gerontology, Vol. 49, Núm. 4, pp. 205-214

  2. Caso Pharmadatum: servicios innovadores en el campo de los análisis de datos procedentes de los ensayos preclínicos y clínicos farmacológicos

    La creación de empresas de base tecnológica: una experiencia práctica (Centro Europeo de Empresas e Innovación de Navarra (CEIN)), pp. 115-122

  3. Population pharmacokinetics of netilmicin in short-term prophylactic treatment

    British Journal of Clinical Pharmacology, Vol. 55, Núm. 6, pp. 552-559

2002

  1. 'In vitro' binding of propofol to serum lipoproteins in thyroid dysfunction

    European Journal of Clinical Pharmacology, Vol. 58, Núm. 9, pp. 615-619

  2. Pharmacokinetics and pharmacological effect of lerisetron, a new 5-HT3 antagonist, in rats

    Journal of Pharmaceutical Sciences, Vol. 91, Núm. 1, pp. 41-52

  3. Prediction of unbound propofol concentrations in a diabetic population

    Therapeutic Drug Monitoring, Vol. 24, Núm. 6, pp. 689-695

2001

  1. Altered disposition and effect of lerisetron in rats with elevated alpha1-acid glycoprotein levels

    Pharmaceutical Research, Vol. 18, Núm. 6, pp. 838-845